Aligos Therapeutics (ALGS)
NASDAQ:ALGS
Want to see ALGS full AI Analyst Report?
Top Page
Aligos Therapeutics
(NASDAQ:ALGS)
Select Model
Select Model
Rating:45Neutral
Price Target:
$5.00
▼(-25.15% Downside)
Action:Reiterated
Date:05/09/26
The score is held down primarily by weak financial performance (large losses and persistent cash burn) and a bearish technical setup (price below key moving averages with negative MACD). Positive corporate events around Fast Track status, interim trial progress, and a licensing deal provide a meaningful offset, while valuation is not clearly supportive given the negative P/E driven by losses.
Positive Factors
Non-dilutive licensing & regional partner
The Amoytop license supplies meaningful non-dilutive capital and shifts development, manufacturing and commercialization responsibilities in Greater China to a well-capitalized partner. That transfers execution risk, accelerates regional development, and preserves ex-China upside and data/IP sharing benefits, improving the company’s ability to fund and de-risk its HBV program over the medium term.
Negative Factors
Persistent cash burn
Consistently negative operating and free cash flow imply the business must repeatedly access external capital or partner deals to fund development. Persistent cash burn constrains optionality, raises dilution or debt risk over a 2–6 month horizon, and limits the company’s ability to run multiple clinical programs or invest strategically without new financing.
Read all positive and negative factors
Positive Factors
Negative Factors
Non-dilutive licensing & regional partner
The Amoytop license supplies meaningful non-dilutive capital and shifts development, manufacturing and commercialization responsibilities in Greater China to a well-capitalized partner. That transfers execution risk, accelerates regional development, and preserves ex-China upside and data/IP sharing benefits, improving the company’s ability to fund and de-risk its HBV program over the medium term.
Read all positive factors
Aligos Therapeutics (ALGS) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$32.67M
Dividend YieldN/A
Average Volume (3M)86.97K
Price to Earnings (P/E)―
Beta (1Y)1.09
Revenue Growth43.88%
EPS Growth14.79%
CountryUS
Employees70
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-8.69
Shares Outstanding5,388,223
10 Day Avg. Volume122,947
30 Day Avg. Volume86,969
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)1.72
Price to Sales (P/S)42.14
P/FCF Ratio-1.11
Enterprise Value/Market Cap0.29
Enterprise Value/Revenue2.01
Enterprise Value/Gross Profit2.26
Enterprise Value/Ebitda-0.10
Forecast
1Y Price Target
$67.60Price Target Upside911.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-7.68
Revenue Forecast (FY)$17.50M
Aligos Therapeutics Business Overview & Revenue Model
Company Description
Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for significant unmet medical needs in both viral and liver diseases. Key candidates in its pipeline include ALG-010133, an s-ant...
How the Company Makes Money
null...
Aligos Therapeutics Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
52
Neutral
Cash Flow
14
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 4.71M | 2.19M | 3.94M | 15.53M | 13.91M | 4.36M |
| Gross Profit | 4.19M | 1.26M | 3.94M | 15.53M | 13.91M | 4.36M |
| EBITDA | -94.34M | -22.95M | -128.26M | -83.81M | -92.27M | -124.41M |
| Net Income | -90.32M | -24.19M | -131.21M | -87.68M | -96.05M | -128.33M |
Balance Sheet | ||||||
| Total Assets | 64.56M | 88.53M | 70.09M | 151.53M | 146.69M | 235.37M |
| Cash, Cash Equivalents and Short-Term Investments | 55.08M | 77.84M | 56.94M | 135.70M | 125.83M | 190.73M |
| Total Debt | 4.35M | 5.25M | 8.38M | 11.14M | 12.57M | 14.46M |
| Total Liabilities | 32.77M | 34.99M | 99.07M | 59.45M | 42.79M | 50.64M |
| Stockholders Equity | 31.79M | 53.55M | -28.97M | 92.08M | 103.90M | 184.73M |
Cash Flow | ||||||
| Free Cash Flow | -85.19M | -82.94M | -80.87M | -79.02M | -80.33M | -116.55M |
| Operating Cash Flow | -84.72M | -82.50M | -80.74M | -79.00M | -79.39M | -115.66M |
| Investing Cash Flow | 41.17M | -37.83M | -18.28M | 44.98M | -26.29M | 3.02M |
| Financing Cash Flow | -169.00K | 101.64M | 355.00K | 88.33M | 164.00K | 78.68M |
Aligos Therapeutics Technical Analysis
Negative
6.68
Price Trends
6.36
Negative
6.82
Negative
8.21
Negative
Market Momentum
-0.33
Negative
42.56
Neutral
35.59
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ALGS, the sentiment is Negative. The current price of 6.68 is above the 20-day moving average (MA) of 5.47, above the 50-day MA of 6.36, and below the 200-day MA of 8.21, indicating a bearish trend. The MACD of -0.33 indicates Negative momentum. The RSI at 42.56 is Neutral, neither overbought nor oversold. The STOCH value of 35.59 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for ALGS.
Aligos Therapeutics Risk Analysis
Aligos Therapeutics disclosed 92 risk factors in its most recent earnings report. Aligos Therapeutics reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Aligos Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
52 Neutral | $29.57M | -0.57 | -70.57% | ― | -100.00% | 21.30% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $61.63M | -0.72 | -64.43% | ― | ― | 9.80% | |
45 Neutral | $32.67M | -0.61 | -139.47% | ― | 43.88% | 14.79% | |
43 Neutral | $21.04M | -0.20 | 411.46% | ― | -51.03% | -35.20% |
* Healthcare Sector Average
ALGS
Aligos Therapeutics
5.28
-2.75
-34.25%
MNOV
Medicinova
1.28
-0.10
-7.25%
CELU
Celularity
0.73
-1.03
-58.75%
BRNS
Barinthus Biotherapeutics
0.72
-0.19
-20.90%
GNTA
Genenta Science SpA Sponsored ADR
1.92
-1.96
-50.52%
ACRV
Acrivon Therapeutics, Inc.
1.44
0.17
13.39%
Aligos Therapeutics Corporate Events
Business Operations and Strategy
Aligos Therapeutics Licenses Hepatitis B Drug Rights to Amoytop
Positive
Apr 21, 2026
On April 16, 2026, Aligos Therapeutics entered into a license agreement with Xiamen Amoytop Biotech granting Amoytop exclusive rights to manufacture, develop and commercialize Aligos’ investigational hepatitis B compound pevifoscorvir sodium...
Business Operations and StrategyProduct-Related AnnouncementsRegulatory Filings and Compliance
Aligos Advances HBV Candidate With Interim Data, Fast Track
Positive
Apr 14, 2026
On April 14, 2026, Aligos Therapeutics reported first interim analysis results from its Phase 2 B-SUPREME trial of pevifoscorvir sodium in adults with chronic hepatitis B virus infection, showing that the independent safety board recommended conti...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.